In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tramadol Reformulations Highlight Pain Challenges and Opportunities

Executive Summary

While reformulating existing drugs can sometimes look like a low risk opportunity, since active substances are already deemed safe and effective, the task is often more complex. The race to develop extended release versions of the now-generic opioid tramadol showcase these technological, clinical and regulatory challenges, while demonstrating that for those who succeed, the upside can be great. A look at Pudue's deal with Labopharm and JNJ's deal with Biovail.
Advertisement

Related Content

Infinity/Purdue: The Challenge of Reprising Roche/Genentech
Infinity/Purdue: The Challenge of Reprising Roche/Genentech
NicOx Eyes Continued Comeback with Second Pfizer Deal
NicOx Eyes Continued Comeback with Second Pfizer Deal
NicOx Eyes Continued Comeback with Second Pfizer Deal
Purdue Flexes Mid-Sized Muscle
Purdue Flexes Mid-Sized Muscle
Grunenthal Learns to Leverage

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel